Management of the axilla II

[1]  I. Lim,et al.  Short‐term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for Stage I or II breast carcinoma , 2004, Cancer.

[2]  H. Sintonen,et al.  The impact of sentinel node biopsy and axillary staging strategy on hospital costs. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  S. Jaffer,et al.  Predictors of nonsentinel lymph node metastasis in breast cancer patients. , 2002, American journal of surgery.

[4]  I. Fentiman,et al.  Occult axillary lymph node metastases are of no prognostic significance in breast cancer , 2002, British Journal of Cancer.

[5]  R. Severson,et al.  Axillary lymph node metastases associated with small invasive breast carcinomas , 1999, Cancer.

[6]  A E Giuliano,et al.  Sentinel-lymph-node biopsy for breast cancer--not yet the standard of care. , 1998, The New England journal of medicine.

[7]  R. Roumen,et al.  Lymphoscintigraphy and feasibility of sentinel node biopsy in 83 patients with primary breast cancer. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  B. Cady,et al.  The need to reexamine axillary lymph node dissection in invasive breast cancer , 1994, Cancer.

[9]  Eleanor Montague,et al.  Comparison of radical mastectomy with alternative treatments for primary breast cancer: A first report of results from a prospective randomized clinical trial , 1977 .